Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mobocertinib - Takeda

Next Previous
X
Search
Drug Profile

Mobocertinib - Takeda

Alternative Names: AP 32788; EXKIVITY; Exkivity; Mobocertinib succinate - Takeda; TAK 788

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Takeda
  • Class Amides; Antineoplastics; Dimethylamines; Esters; Ethers; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action BLK protein inhibitors; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 11 Oct 2023 Updated pharmacodynamics and adverse events data from a phase I/II in NSCLC presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 02 Oct 2023 Withdrawn for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 02 Oct 2023 Takeda plans to withdraw Mobocertinib for the treatment of Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in all the countries where it is currently registered no later than March 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top